The process from lead molecule identification to completion of a first‑in‑human trial can be long and complicated. But with Altasciences’ Proactive Drug Development solution, your timelines can be reduced by up to 40%. Your entire program will be managed by one organization and overseen by a single, cross-functional program manager to quickly and seamlessly advance your molecule from preclinical testing to first‑in‑human clinical trials, and beyond—helping you get your medicines to the people who need them, faster.

Learn more by downloading our eBook.

Altasciences keeps you on track, milestone to milestone.

Avoid delays caused by operational roadblocks, miscommunications, and lack of data sharing. 

Discover a simpler way to drug development success and how Altasciences’ integrated end-to-end CRO/CDMO solutions can safely move your molecule seamlessly from one phase to the next, and to market faster.

Start Watching!

Got 5 more minutes? Check out: 

• Webpage: Our Full Array of Drug Development, Manufacturing, and Analytical Solutions
• Scientific Paper: Benefits of Liquid-Filled Capsules Versus Tablets in Pharmaceutical Development

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.

Biomarkers Inform the Drug Development Process for Large and Small Molecule Drugs

Altasciences can extract meaningful data from measuring various intracellular, membrane-bound, and secreted circulating biomarkers to inform the development process.

We will help guide you towards a robust and fit-for-purpose biomarker solution involving veteran scientists, toxicologists and clinical pharmacologists to develop a comprehensive preclinical to clinical plan to maximize the translation of results from one phase to the next. 

Let’s get started!

You may also be interested in the following:

• Biomarkers and Biosimilars list
• Bioanalytical Services
• Comprehensive Research Support Services

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.

One-Stop Solution for Meeting Your Needs in Outsourcing Drug Development

Altasciences recently conducted a survey to understand the challenges biopharmaceutical companies face when outsourcing their early phase drug development programs. Over 143 executives shared the important factors that guide them in the selection of a CRO partner.

Their candid testimonials are shared in this playbook, including:

• The significant challenges encountered when conducting preclinical and Phase I studies
• The unique difficulties of transitioning from preclinical to first-in-human studies 
• The specific capabilities and expertise executives look for in their CRO partners
• The novel drug development solution approach for addressing the challenges encountered

Download your copy today.

Let us help!  Speak with our experts today.

You may also be interested in the following:

Webpages:

• Proactive Drug Development
• Early Phase Drug Development Solutions

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.

Moving in Unison to Bring Your Vision to Life 

Trust is an important factor in any relationship. And we know trust is earned. 

That’s why at Altasciences, our focus is on you. We build strong relationships with each client through quality science and  proactive, responsive, and transparent communication that ensures you only have to Tell Us Once™. 

When you choose us, you are choosing a partner that will work as an extension of your team — who treats you like colleagues and your projects as our own. We’ll work side by side, getting to know your goals and understanding your needs. From preclinical to clinical proof of concept, and beyond, we’ll advance your molecule in one integrated, seamless process, celebrating your milestones together. 

Why? Because drug development isn’t a transaction — it’s a journey. Speak with an Altasciences expert to start your journey.
 

Watch this video to discover what it means to partner with Altasciences:

Have five minutes? Take a look at these: 

• Check out our new interactive brochure
• Discover our Proactive Drug Development solution
• Read this blog article: Moving Your Drug Forward to Preclinical Trials
• Explore our customizable and flexible early phase solution offering
• Read this Q&A featuring Marie-Hélène Raigneau, our Co-Chief Operating Officer​​​​​

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.

Highlights of Our Kansas City Research Campus

Altasciences’ clinical facilities are dedicated to the conduct of early phase and clinical pharmacology trials in a wide range of therapeutic areas. Our Kansas City clinical facility works in unison with our 6 other sites to offer an integrated drug development solution from lead candidate selection to clinical proof of concept and beyond. With over 25 years of experience, conducting 285+ trials annually, our clinics are flexible and adaptable for single or multi-site clinical trials. 

Our Kansas City purpose-built clinic features:

• 140 beds
• On-site USP 797 certified pharmacy 
• 36-bed specialty clinical unit for sequestering patient populations
• Upscale facility with accommodations that ensures best recruitment and retention
• Dedicated QT unit 
• Principal Investigators with psychiatry and epidemiology specializations
• Neuro/CNS specialization — over 40 Human Abuse Potential (HAP) studies conducted
• Full-service capabilities including bio analysis, manufacturing, designing, conducting, and reporting on clinical pharmacology studies required for regulatory submission.

Virtually step inside our KC clinic here.

You may also be interested in the following:

Webpages:

• Our Clinical Trial Facilities
• CNS Clinical Trial Capabilities

Video: Quick Chat with Dr. Kelsh — Leader in CNS and Human Abuse Liability Studies

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.

Our Commitment to You

Your new drug could be the one that changes someone’s life. As investors in life sciences, we know that each project matters. Whether you place one study or multiple programs with us, we treat each project with the equal care and dedication it deserves, no matter the size or spend. 

We are committed to making your project a success. After all, your success is our success. And our success, together, means getting better drugs to people who need them, faster.

Speak with an Altasciences expert today. 

TAKE FIVE:

• Watch this video to experience the difference
• Check out our new interactive brochure
• Discover our Proactive Drug Development approach
• Read this blog article: Five Ways Altasciences Simplifies the Drug Development Process for You
• Catch up on our top scientific resources of 2021

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.